Once daily oral direct factor Xa inhibitor rivaroxaban (BAY59-7939) in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension Study.

Trial Profile

Once daily oral direct factor Xa inhibitor rivaroxaban (BAY59-7939) in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Registrational; Therapeutic Use
  • Acronyms EINSTEIN-EXT
  • Sponsors Bayer
  • Most Recent Events

    • 30 Nov 2012 Pooled data from EINSTEIN-DVT, EINSTEIN-PE and EINSTEIN-EXT will be presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition, according to a Bayer HealthCare media release.
    • 02 May 2012 Results from this trial have been used in support of supplemental new drug applications in USA for the use of rivaroxaban to treat venous thromboembolism (deep vein thrombosis or pulmonary embolism) and to prevent recurrent venous thromboembolism.
    • 28 Jul 2011 Results of an analysis identifying subgroups who were at decreased risk for VTE presented at the 23rd Congress of the International Society on Thrombosis and Haemostasis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top